The online reference source for the interventional NeuroRadiology, Neurology and NeuroSurgery community
>Discussing the expansion of INR tools available today and the first-in-man experience with the PEGASUS HPC stent system…
Discussing the expansion of INR tools available today and the first-in-man experience with the PEGASUS HPC stent system…
Wondering how to keep track of the rapid changes in the field of interventional neuroradiology (INR)? Join Prof. Markus HOLTMANNSPÖTTER in this discussion at the recent LINNC Paris 2021 touching on such diverse topics as stroke, the large diversity of tools we have at our disposal, a novel remodeling stent for treating aneurysms, and vistas in INR training.
Since the beginning of mechanical thrombectomy, we have witnessed the ongoing development and expansion of the tools at our disposal that help facilitate the procedure but, as Prof. HOLTMANNSPÖTTER points out, how do we obtain the experience that allows us to choose which of these new devices corresponds to the individual needs of a specific intervention? While the tools have become easier to use, the early ones required a level of expertise which allowed the specialist to understand, perhaps in a more profound and hands-on way, the mechanics and challenges involved in each intervention. Prof. HOLTMANNSPÖTTER reflects on the ways clinical training has evolved to respond to this challenge, enabling the experienced interventional neuroradiologist to translate their skill set to others. Is there a role that simulation or robotics can play in this new idea of training?
Considering new devices, Prof. HOLTMANNSPÖTTER spoke about his first-in-man experience with the PEGASUS HPC stent system – a remodeling open-cell stent for treating aneurysms which incorporates a thrombogenic-reducing coating. This coating has only previously been available for flow diverters – why not for other implants?
In the case Prof. HOLTMANNSPÖTTER presented during LINNC Paris 2021, the patient treated with the PEGASUS HPC device had been premedicated with an antioxidant, making the addition of dual antiplatelet therapy an increased bleeding risk. Using the coated stent allowed Prof. HOLTMANNSPÖTTER to choose a single antiplatelet therapy which, if shown to be safe, could have an important impact on future patient selection, allowing for the inclusion of patients with comorbidities or concomitant diseases, a more frequent situation as the population ages.
In conclusion, Prof. Markus HOLTMANNSPÖTTER sums up his LINNC experience underlining the importance of in-person sharing with expert teams from around the world. Looking into “each other’s kitchens” Prof. HOLTMANNSPÖTTER says, allows us to have insights into our own clinical practice, which advances the discipline for everyone, patient and specialist alike. See what he means here…
How has the role of surgery evolved with the development of endovascular techniques?